Increased risk of cerebrovascular events in @entity1 with XXXX treated with bevacizumab: a meta-analysis.

@entity1 @entity548 @entity7 @entity5 @entity63 @entity14
@entity63 and @entity548 are associated with bevacizumab, an inhibitor of @entity7 that is widely used to treat many types of @entity5 . As specific types of @entity63 and @entity548 , cerebrovascular events such as central nervous system (CNS) @entity63 events and CNS @entity548 are serious adverse events. However, increased cerebrovascular events have not been uniformly reported by previous studies. New randomized controlled trials (RCTs) have been reported in recent years and we therefore conducted an up-to-date meta-analysis of RCTs to fully characterize the risk of cerebrovascular events with bevacizumab. We searched the databases of PubMed, Web of Science, and the American Society of Clinical Oncology conferences to identify relevant clinical trials up to February 2014. Eligible studies included prospective RCTs that directly compared @entity1 with @entity5 treated with and without bevacizumab. A total of 12,917 @entity1 from 17 RCTs were included in our analysis. @entity1 treated with bevacizumab had a significantly increased risk of cerebrovascular events compared with @entity1 treated with control medication, with a relative risk of 3.28 (95% CI, 1.97-5.48). The risks of CNS @entity63 events and CNS @entity548 were increased compared with control, with RRs of 3.22 (95% CI, 1.71-6.07) and 3.09 (95% CI, 1.36-6.99), respectively. Risk varied with the bevacizumab dose, with RRs of 3.97 (95% CI, 2.15-7.36) and 1.96 (95% CI, 0.76-5.06) at 5 and 2.5 mg/kg/week, respectively. Higher risks were observed in @entity1 with metastatic @entity14 (RR, 6.42; 95% CI, 1.76-35.57), and no significant risk was observed in other types of @entity5 . In conclusion, the addition of bevacizumab significantly increased the risk of cerebrovascular events compared with controls, including CNS @entity63 events and CNS @entity548 . The risk may vary with bevacizumab dose and @entity5 type.
